首页 | 本学科首页   官方微博 | 高级检索  
     


The challenge of CDG diagnosis
Authors:R. Francisco  D. Marques-da-Silva  S. Brasil  C. Pascoal  V. dos Reis Ferreira  E. Morava  J. Jaeken
Affiliation:1. UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal;2. Portuguese Association for CDG, Lisboa, Portugal;3. CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Portugal;4. Department of Clinical Genomics, CIM, Mayo Clinic, Rochester, MN, United States;5. Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium
Abstract:Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement.This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.
Keywords:CDG  Diagnosis  MS  NGS  Whole Exome Sequencing  Molecular testing  AChR  Acetylcholinesterase receptor  ALP  Alkaline phosphatase  ALT  Alanine aminotransferase  ApoC-III  Apolipoprotein C-III  APPT  Activated partial thromboplastin time  AST  Aspartate transaminase  CDG  Congenital Disorder(s) of Glycosylation  CK (-MB)  Creatine kinase (-Muscle/brain)  CKP  Creatine phosphokinase  DAG  Dystroglycan  DHEA  Dehydroepiandrosterone  ERG  Electroretinography  FGF23  Fibroblast growth factor 23  FSH  Follicle stimulating hormone  GalNAc  N-Acetylgalactosamine  GlcNAc  N-Acetylglucosamine  GDP  Guanosine diphosphate  GPI  Glycosylphosphatidylinositol  ICAM1  Intercellular Adhesion Molecule 1  IEF  Isoelectrofocusing  QTOF  Quadrupole time-of-flight  LAMP2  Lysosome-associated membrane protein 2  LGMD  Limb-girdle muscular dystrophy  LLO  Lipid-linked oligosaccharide  LH  Luteinizing hormone  ManNAc  MS  Mass spectrometry  NA  Not applicable/not available  NCAM1  Neural cell adhesion molecule 1  NGS  Next generation sequencing  NK  Natural Killer  PI-PLC  Phosphoinositide-phospholipase C  PHPV  Persistent hyperplastic primary vitreous  SA  Sialic acid  SLeX  Sialyl-Lewis X  Tf  Transferrin  UDP  Uridine diphosphate  VEP  Visual evoked potentials  WES  Whole exome sequencing  WGS  Whole genome sequencing
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号